Abstract:Introduction SCBC is an aggressive subtype of bladder cancer with high metastatic potential and few effective therapies. The defining mutations of neuroendocrine cancers include loss-of-function mutations in p53 and Rb and gain-of-function mutations in driver oncogenes (e.g., MYC). We engineered an orthotopic mouse model of SCBC leveraging these defining mutations to investigate the genetic and epigenetic drivers of SCBC. Methods Lentiviral particles carrying Cre recombinase were produced using Lenti-sgNeo#2/Cre. The bladders of genetically engineered Rb1fl/fl Trp53fl/fl MycLSL/LSL (RPM) mice were transduced with Cre recombinase-expressing lentivirus via transurethral catheterization. Mice were monitored by micro-ultrasound (mUS) and bioluminescent imaging and detected tumors were verified by histology. SCBC morphology was confirmed by hematoxylin and eosin (H&E) staining and synaptophysin immunohistochemistry (IHC) by a genitourinary pathologist. Whole transcriptome (RNAseq) analysis was performed to correlate transcriptomic profile of neuroendocrine mouse tumors to a cohort of human SCBC tumors. Candidate driver genes were prioritized and association with prognosis in human tumors was evaluated (TCGA BLCA, n=417). The function of Forkhead box protein family members coordinately up and down regulated in human and murine SCBC was investigated in human urothelial carcinoma and murine syngeneic cell lines. Results Transurethral catheterization successfully transduced the bladder urothelium without evidence of ectopic (non-urothelial) exposure. RPM mice developed SCBC visible on mUS and bioluminescent imaging within 8-10 weeks. As expected in neuroendocrine tumors, mice developed spontaneous visceral and lung metastases. High grade neuroendocrine morphology and NE markers were confirmed on H&E staining and IHC, respectively, by our genitourinary;pathologist. Western blot analysis confirmed Myc expression and suppression of TP53 and RB1. Transcriptomic profiling of both mouse and human SCBC demonstrated concordant gene expression. Gene expression profiling of mouse neuroendocrine bladder tumors and normal bladder showed increased FOXA2 expression in the tumor and high intratumoral FOXA2 protein expression was confirmed on IHC. TCGA-BLCA analysis showed significantly worse overall survival for patients whose bladder tumors overexpressed FOXA2 (p=0.01). Expression of FOXA2 in human urothelial cancer lines harboring p53 and RB mutations led to increased expression of neuroendocrine markers by immunocytochemistry. Conclusions We developed a novel genetically engineered orthotopic murine model of SCBC which is histologically and morphologically similar to human SCBC. Gene expression profiling of neuroendocrine bladder tumors from these mice suggest FOXA2 may play a role in the initiation and development of the neuroendocrine phenotype. Ongoing work seeks to further characterize the role of FOXA2 in neuroendocrine differentiation and identify other genetic and epigenetic markers that may cooperatively contribute to the development of this aggressive variant of bladder cancer.

Impaired cognition in depression and Alzheimer (AD): a gradient from depression to depression in AD.

Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype.

Pharmaceutical and personal care products in sewage treatment works.

Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.

Ezetimibe use remains common among medical inpatients.

A Clinicopathological and Molecular Analysis of Cervical Carcinomas with Basaloid Features

Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile

Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up

Treatment and survival of non-metastatic small cell carcinoma of the bladder from multiple centers in China

Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes

Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing

Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy

A clinical appraisal of neomycin.

Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis

MEMBRANE MARKERS OF LYMPHOCYTES IN LYMPHOMAS, MELANOMA AND LUPUS ERYTHEMATOSUS

Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer

Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer

Diagnosis and Treatment of Primary Small Cell Carcinoma of the Urinary Bladder

Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder

A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC)

[Steroid hormones in plasma and aqueous of bovine eye].